Can a diabetes drug help fight liver cancer? a trial puts it to the test

This trial investigates whether adding dapagliflozin—a drug typically used for diabetes—to standard first-line therapy can improve tumor response in people with advanced liver cancer that cannot be surgically removed and who also have metabolic syndrome. About 44 participants will receive either the standard therapy alone or standard therapy plus dapagliflozin. Researchers will compare how well the tumors shrink and how long patients live or go without the cancer worsening.